[Pharmacological biomodulation in cancer].
The discovery of the P-glycoprotein as a mediator of multidrug resistance (MDR) represents one of the most important research accomplishments in antineoplastic pharmacology during the last decade. Demonstration of Pgp in epithelial tissues, untreated and chemotherapeutically pretreated human malignancies, and identification of various agents capable of reversing in vitro resistance has generated enthusiasm for clinical studies throughout the world. This review discusses recent developments of experimental and clinical investigations of MDR reversing agents in cancer.
Arvelo
F
F
Laboratorio de Cultivo de Tejidos y Biología de Tumores, Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela, Apartado Postal 47114, Caracas, 1041-A Venezuela.
Merentes
E
E
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D010641:Phenotype
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002121:Calcium Channel Blockers; D007155:Immunologic Factors
Biomodulación farmacológica en cáncer.